Skip to main content

CervoMed Inc.

corporate_fare Company Profile

CervoMed Inc.

CRVO·NASDAQ·Life Sciences·CIK 0001053691

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders. The company's primary drug candidate is neflamapimod, an investigational, orally administered small-molecule drug. Neflamapimod is designed to cross the blood-brain barrier and selectively inhibit the enzyme p38α, which is a key contributor to neuroinflammation and synaptic dysfunction. By targeting these critical disease processes, neflamapimod aims to reverse synaptic dysfunction, improve neuron health, and potentially slow or prevent disease progression. Neflamapimod is currently undergoing clinical development for several conditions. Its lead indication is the treatment of Dementia with Lewy Bodies (DLB). It is also being developed for non-fluent variant primary progressive aphasia (nfvPPA), Rett Syndrome (RAS), and Amyotrophic Lateral Sclerosis (ALS). The company's approach emphasizes reducing the impact of neuroinflammation, which is considered a significant factor in the development of degenerative brain diseases. Chronic activation of p38α in individuals with certain neurodegenerative diseases is thought to impair neuronal communication through synapses, leading to a decline in cognitive and motor abilities. CervoMed Inc. believes that inhibiting p38α activity could reverse early clinical progression and delay permanent synaptic dysfunction and neuron death. The company considers itself a leader in developing a treatment for DLB, a condition with no approved therapies in the US or European Union. Neflamapimod is reported to be the only clinical drug candidate that has demonstrated statistically significant improvements on clinical endpoints and a biomarker of neurodegeneration in both a Phase 2a and Phase 2b clinical trial.

CervoMed Inc. (NASDAQ:CRVO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 41 items for CRVO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for CRVO spans 4, 10-Q, 8-K, 424B3.

Recent high-impact activity:

  • CEO John Alam Buys 100,000 CRVO Shares for $152,621 Near 52-Week Low
  • Neflamapimod Shows Exposure-Dependent NfL Reduction at 24 Weeks in nfvPPA
  • CervoMed Q3 Loss Narrows to $5.9M but Going Concern Doubt Persists on $19.6M Cash
  • CervoMed Publishes Phase 2b DLB Data; Primary Endpoint Missed in Full Population
  • CervoMed's Neflamapimod Shows NfL Reduction in nfvPPA Phase 2a

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.01M
Net Income
-$26.97M
Op. Cash Flow
-$23.45M
Operating Income
-$28.29M
Cash & Equivalents
$8.24M
Debt / Equity
0.00×
Net Margin
-6.73×
Shares Outstanding
9.25M sh
Source: 10-K · filed 2026-03-13 · accession 0001437749-26-008259

Short Interest & Short Volume

4.65 days to cover

FINRA reported short interest of 1,212,655 shares in CRVO as of the October 30, 2026 settlement, a 0.4% increase from the prior period — about 4.7 days to cover at its recent average daily volume. On November 20, 2026, 53.6% of CRVO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,212,655 shares as of October 30, 2026
Change vs prior period▲ 0.4%
Days to cover4.65 at avg daily volume of 260,594
Daily short volume (FINRA facilities)53.6% of 680,130 shares on November 20, 2026
5-day average short volume50.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for CRVO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-10.

1 recent capital raise1 shelf registration

Registered Direct Offering Finalized · Premium Pricing Achieved

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$1.44 -1.30% today
52-week range · as of 2026-11-20 $1.27 – $10
Market cap
$22.09M
Volume
1.2M (1.5× avg)
3-mo avg 801.3K
Live data · 2026-11-21 18:29 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRVO - Latest Insights

CRVO
Nov 19, 2026, 9:03 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $1.44 info
Change: +$0.1237 (+9%) info
Market Cap: $22.088M info
CRVO
Nov 16, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.44 info
Change: -$0.209 (-13%) info
Market Cap: $22.088M info
CRVO
Nov 06, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $1.44 info
Change: +$0.021 (+1%) info
Market Cap: $22.088M info
CRVO
Oct 29, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.44 info
Change: -$0.309 (-18%) info
Market Cap: $22.088M info
CRVO
Oct 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $1.44 info
Change: -$1.58 (-52%) info
Market Cap: $22.088M info
CRVO
Sep 28, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.44 info
Change: -$1.19 (-45%) info
Market Cap: $22.088M info
CRVO
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.64
Real-time Price: $1.44 info
Change: -$1.19 (-45%) info
Market Cap: $22.088M info
CRVO
Aug 10, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.87
Real-time Price: $1.44 info
Change: -$1.43 (-50%) info
Market Cap: $22.088M info
CRVO
Aug 04, 2026, 7:52 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $1.44 info
Change: -$1.24 (-46%) info
Market Cap: $22.088M info
CRVO
Aug 04, 2026, 5:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.59
Real-time Price: $1.44 info
Change: -$1.15 (-44%) info
Market Cap: $22.088M info
CRVO
Jul 14, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.12
Real-time Price: $1.44 info
Change: -$1.68 (-54%) info
Market Cap: $22.088M info
CRVO
Jul 10, 2026, 5:27 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $3.56
Real-time Price: $1.44 info
Change: -$2.12 (-60%) info
Market Cap: $22.088M info
CRVO
Jul 09, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $1.44 info
Change: -$2.31 (-62%) info
Market Cap: $22.088M info
CRVO
Jul 09, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.42
Real-time Price: $1.44 info
Change: -$1.98 (-58%) info
Market Cap: $22.088M info
CRVO
Jul 06, 2026, 5:00 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $3.57
Real-time Price: $1.44 info
Change: -$2.13 (-60%) info
Market Cap: $22.088M info
CRVO
Jul 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.60
Real-time Price: $1.44 info
Change: -$2.16 (-60%) info
Market Cap: $22.088M info
CRVO
Jun 22, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $1.44 info
Change: -$2.59 (-64%) info
Market Cap: $22.088M info
CRVO
Jun 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.03
Real-time Price: $1.44 info
Change: -$2.59 (-64%) info
Market Cap: $22.088M info
CRVO
Jun 22, 2026, 6:16 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.85
Real-time Price: $1.44 info
Change: -$2.41 (-63%) info
Market Cap: $22.088M info
CRVO
Jun 18, 2026, 8:58 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.91
Real-time Price: $1.44 info
Change: -$2.47 (-63%) info
Market Cap: $22.088M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets